Tennis civil war takes twist amid allegations of 'coercive behavior'PODCAST: Why big pharma is terrified of RFK appointment.

formerly known as Axovant and one of the 'vant' companies originally founded by entrepreneur Vivek Ramaswamy. Sio's board of directors has decided it is time to call it quits and abandon the ...

Switzerland-based biopharma start-up Enzyvant has gained a double fast track status from the FDA for its new rare disease candidate RVT-802. The investigational tissue-based therapy is for the ...

The approach represents an interesting contrast to companies such as Roivant, which are built on the premise of buying drugs shelved by big pharma. Roivant’s founder Vivek Ramaswamy believes his ...

Axovant is founded and financed by Roivant and its CEO Vivek Ramaswamy, whose central strategy is to buy drugs that have been abandoned or shelved by big pharma and successfully bring them to market.

In Roivant, Pfizer has a partner with "a proven track record in late-stage inflammation and immunology drug development," said the big ... by entrepreneur Vivek Ramaswamy – which specialises ...